Protalix BioTherapeutics, Inc. Form 8-K November 09, 2016

# **UNITED STATES**

### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT** 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 9, 2016

**Protalix BioTherapeutics, Inc.** 

(Exact name of registrant as specified in its charter)

Edgar Filing:	Protalix	BioTherapeutics,	Inc Form 8-K

(State or other jurisdiction (Commission File Number) of incorporation)

(IRS Employer

**Identification No.**)

2 Snunit Street Science Park, POB 455 Carmiel, Israel 20100 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code +972-4-988-9488

### (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### Item 2.02. Results of Operations and Financial Condition

On November 9, 2016, Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2016. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

#### Item 9.01. Financial Statements and Exhibits

#### (d) Exhibits

99.1 Press release dated November 9, 2016.

# SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## PROTALIX BIOTHERAPEUTICS, INC.

Date: November 9, 2016	By:	/s/ Moshe Manor
		Moshe Manor
	Name:	President and
	Title:	Chief Executive
		Officer